Avanir Pharmaceuticals announces positive interim data from study with AVP-786 Avanir Pharmaceuticals announced that it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data, Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923. The company has requested a meeting with the FDA to discuss the full development path for AVP-786. Avanir also announced today that the company intends to modify the enrollment target of its ongoing phase II clinical study of AVP-923 in central neuropathic pain in multiple sclerosis to 200 patients. As a result of this change, the company now expects to have data from the PRIME study in the fourth calendar quarter of 2013.